Second malignant neoplasm in patients with osteosarcoma of the extremities treated with adjuvant and neoadjuvant chemotherapy

Journal of Pediatric Hematology/Oncology

Volumn 28, Issue 12, 2006, Pages 774-780

  Bacci, Gaetano ^a,f   Ferrari, Cristina ^b   Longhi, Alessandra ^a   Ferrari, Stefano ^a   Forni, Cristiana ^a   Bacchini, Patrizia ^c   Palmerini, Emanuela ^a   Briccoli, Antonio ^d   Pignotti, Elettra ^e   Balladelli, Alba ^b   Picci, Piero ^b  

^a Chemotherapy   (Italy)

^b Laboratory of Oncologic Research   (Italy)

^c Pathology   (Italy)

^d Istituti Ortopedici Rizzoli   (Italy)

^e Istituti Ortopedici Rizzoli   (Italy)

^f Sezione di Chemioterapia   (Italy)

Author keywords

Cancer risk after treatment; Chemotherapy; Osteosarcoma

Indexed keywords

BLEOMYCIN; CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; METHOTREXATE;

ADOLESCENT; ADULT; ARTICLE; BENIGN TUMOR; BREAST CANCER; CANCER ADJUVANT THERAPY; CENTRAL NERVOUS SYSTEM TUMOR; CHILD; CLINICAL ARTICLE; COLON CANCER; CONTROLLED STUDY; DISEASE FREE INTERVAL; FEMALE; HUMAN; KIDNEY CANCER; LATENT PERIOD; LEUKEMIA; LIMB; LUNG CANCER; MALE; OSTEOSARCOMA; PAROTID GLAND CANCER; PRIORITY JOURNAL; SECOND CANCER; SOFT TISSUE CANCER; SOLID TUMOR; STATISTICAL SIGNIFICANCE;

ADOLESCENT; ADULT; CHEMOTHERAPY, ADJUVANT; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INCIDENCE; INFANT; MALE; NEOPLASMS; NEOPLASMS, SECOND PRIMARY; OSTEOSARCOMA; RETROSPECTIVE STUDIES; RISK FACTORS; SEX FACTORS; TIME FACTORS;

EID: 33845687703     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/01.mph.0000243664.02174.73     Document Type: Article

References (32)

1. Rosen G, Caparros B, Huvos AG, et al. Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer. 1982;49:1221-1230.
2. Winkler K, Beron G, Delling G, et al. Neoadjuvant chemotherapy of osteosarcoma: results of a randomized cooperative trial (COSS-82) with salvage chemotherapy based on histological tumor response. J Clin Oncol. 1988;6:329-337.
3. Meyers PA, Heller G, Healey J, et al. Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience. J Clin Oncol. 1992;10:5-15.
4. Provisor AJ, Ettinger LJ, Nachman JB, et al. Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children's Cancer Group. J Clin Oncol. 1997;15:76-84.
5. Fuchs N, Bielack SS, Epler D, et al. Long-term results of the co-operative German-Austrian-Swiss osteosarcoma study group's protocol COSS-86 of intensive multidrug chemotherapy and surgery for osteosarcoma of the limbs. Ann Oncol. 1998;9:893-899.
6. Goorin AM, Schwartzentruber DJ, Devidas M, et al. Pediatric Oncology Group. Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for nonmetastatic osteosarcoma: Pediatric Oncology Group Study POG-8651. J Clin Oncol. 2003;21:1574-1580.
7. Beaty O III, Hudson MM, Greenwald C, et al. Subsequent malignancies in children and adolescents after treatment for Hodgkin's disease. J Clin Oncol. 1995;13:603-609.
8. Russo CL, McIntyre J, Goorin AM, et al. Secondary breast cancer in patients presenting with osteosarcoma: possible involvement of germline p53 mutations. Med Pediatr Oncol. 1994;23:354-358.
9. Knowling MA, Basco VE. Breast cancer after treatment for osteosarcoma. Med Pediatr Oncol. 1986;14:51-53.
10. Ikeda T, Sekiguchi C, Shimamura K, et al. Breast cancer developing after chemotherapy for osteosarcoma: a case report [review]. Jpn J Clin Oncol. 1991;21:444-446.
11. Pratt CB, Meyer WH, Luo X, et al. Second malignant neoplasms occuring in survivors of osteosarcoma. Cancer. 1997;80:960-965.
12. Aung L, Gorlick RG, Shi W, et al. Second malignant neoplasms in long-term survivors of osteosarcoma: Memorial Sloan-Kettering Cancer Center Experience. Cancer. 2002;95:1728-1734.
13. Hauben EI, Arends J, Vandenbroucke JP, et al. Multiple primary malignancies in osteosarcoma patients. Incidence and predictive value of osteosarcoma subtype for cancer syndromes related with osteosarcoma. Eur J Hum Genet. 2003;11:611-618.
14. Fletcher CDM, Unni KK, Mertens F. World Health Organization Classification of Tumours. Pathology and Genetics of Tumors of Soft Tissue and Bone. Lyon: IARC Press; 2002:314-367.
15. Campanacci M, Bacci G, Bertoni F, et al. The treatment of osteosarcoma of the extremities: twenty year's experience at the Istituto Ortopedico Rizzoli. Cancer. 1981;48:1569-1581.
16. Bacci G, Gherlinzoni F, Picci P, et al. Adriamycin-methotrexate high dose versus adriamycin-methotrexate moderate dose as adjuvant chemotherapy for osteosarcoma of the extremities: a randomized study. Eur J Cancer Clin Oncol. 1986;22:1337-1345.
17. Bacci G, Picci P, Ruggieri P, et al. Primary chemotherapy and delayed surgery (neoadjuvant chemotherapy) for osteosarcoma of the extremities. The Istituto Rizzoli Experience in 127 patients treated preoperatively with intravenous methotrexate (high versus moderate doses) and intraarterial cisplatin. Cancer. 1990;65:2539-2553.
18. Bacci G, Picci P, Ferrari S, et al. Primary chemotherapy and delayed surgery for nonmetastatic osteosarcoma of the extremities. Results in 164 patients preoperatively treated with high doses of methotrexate followed by cisplatin and doxorubicin. Cancer. 1993;72:3227-3238.
19. Ferrari S, Mercuri M, Picci P, et al. Nonmetastatic osteosarcoma of the extremity: results of a neoadjuvant chemotherapy protocol (IOR/OS-3) with high-dose methotrexate, intraarterial or intravenous cisplatin, doxorubicin, and salvage chemotherapy based on histologic tumor response. Tumori. 1999;85:458-464.
20. Bacci G, Ferrari S, Longhi A, et al. Italian Sarcoma Group/Scandinavian Sarcoma Group. High dose ifosfamide in combination with high dose methotrexate, adriamycin and cisplatin in the neoadjuvant treatment of extremity osteosarcoma: preliminary results of an Italian Sarcoma Group/Scandinavian Sarcoma Group pilot study. J Chemother. 2002;14:198-206.
21. Hryniuk W, Bush H. The importance of dose intensity in chemotherapy of metastatic breast cancer [review. No abstract available]. J Clin Oncol. 1984;2:1281-1288.
22. Enneking WF, Spanier SS, Goodman MA. A system for the surgical staging of musculoskeletal sarcoma. Clin Orthop Relat Res. 1980;153:106-120.
23. Picci P, Bacci G, Campanacci M, et al. Histologic evaluation of necrosis in osteosarcoma induced by chemotherapy. Regional mapping of viable and nonviable tumor. Cancer. 1985;56:1515-1521.
24. Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data. New York: John Wiley & Sons Inc; 1980.
25. Draper GJ, Sanders BM, Kingston JE. Second primary neoplasms in patients with retinoblastoma. Br J Cancer. 1986;53:661-671.
26. Abramnson DH, Ellsworth RM, Kitchin FD. Second non ocular tumors in retinoblstoma. Ophthalmology. 1984;91:1352-1355.
27. Green DM, Zevon MA, Reese PA, et al. Second malignant tumors following treatment during childhood and adolescence for cancer. Med Pediatr Oncol. 1994;22:1-10.
28. Rosso P, Terracini B, Fears TR, et al. Second malignant tumors after elective end of therapy for a first cancer in childhood: a multicenter study in Italy. Int J Cancer. 1994;59:451-456.
29. Jacobs AD, Gale RP. Acute myelogenous leukemia following radiation therapy and chemotherapy for osteogenic sarcoma. Cancer Treat Rep. 1984;68:909-911.
30. Kapelushnik J, Dube I, Wilson P, et al. Acute lymphoblastic leukemia with t(4;11) translocation after osteogenic sarcoma. Cancer. 1991;67:2887-2889.
31. Pappo A, Schneider NR, Sanders JM, et al. Secondary myelodysplastic syndrome complicating therapy for osteogenic sarcoma [review]. Cancer. 1991;68:1373-1375.
32. Pui CH, Ribeiro RC, Hancock ML, et al. Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia. N Engl J Med. 1991;325:1682-1687.